Dr. Westin on the Evolving Landscape of CAR T-Cell Therapy in NHL


In Partnership With:

Jason R. Westin, MD, discusses the evolving landscape of CAR T-cell therapy in non-Hodgkin lymphoma.

Jason R. Westin, MD, director, Lymphoma Clinical Research, section chief, Aggressive Lymphoma, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolving landscape of CAR T-cell therapy in non-Hodgkin lymphoma (NHL).

It remains undetermined which patients with NHL are the most suitable for CAR T-cell therapy, Westin says. Previously, transplant-eligible patients were considered candidates, though this system relied on a more subjective assessment and vaguer criteria, such as organ function performance status and laboratory assessments, Westin explains. These assessments were done to determine which patients could tolerate high-dose chemotherapy, Westin adds.

However, based on the influx of various data from patient reported outcomes and trials, CAR T cells could provide a benefit for patients who, historically, have not been considered transplant eligible, Westin adds.

CAR T-cell therapy could be less toxic and better tolerated by some of the patients who may not have tolerated high dose chemotherapy, Westin continues. Expanding the use of CAR T-cell therapy in more patients with NHL could provide curative options to a larger portion of the population, Westin concludes.

Related Videos
Jose A. Karam, MD, FACS
Amer Zeidan, MBBS
Eric Jonasch, MD
Ulka Nitin Vaishampayan, MBBS
Erica L. Mayer, MD, MPH
Christopher M. Gallagher, MD
Lyudmila A. Bazhenova, MD
Benjamin Philip Levy, MD
John N. Allan, MD
Nicole Lamanna, MD